A carregar...

Mutant HRAS as novel target for MEK and mTOR inhibitors

HRAS is a frequently mutated oncogene in cancer. However, mutant HRAS as drug target has not been investigated so far. Here, we show that mutant HRAS hyperactivates the RAS and the mTOR pathway in various cancer cell lines including lung, bladder and esophageal cancer. HRAS mutation sensitized towar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Kiessling, Michael K., Curioni-Fontecedro, Alessandra, Samaras, Panagiotis, Atrott, Kirstin, Cosin-Roger, Jesus, Lang, Silvia, Scharl, Michael, Rogler, Gerhard
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4747218/
https://ncbi.nlm.nih.gov/pubmed/26544513
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!